Safaa Mahmoud

بسم اللّه الرحمن الرحيم

مركز الشبكات وتكنولوجيا المعلومات

قسم التوثيق الإلكتروني

Safaa Mahmoud

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم باللّه العظيم أن المادة التي تم توثيقها وتسجيلها

علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات

Potential role of hepatic stem/progenitor cells immunoexpression as a predictor to interferon response in Egyptian HCV patients

Thesis

Submitted for Partial Fulfillment of M.D. Degree
in **Pathology**

By

Heba Ahmed Mahmoud Mohammed

M.B.B.CH, Msc. Pathology
Faculty of Medicine, Ain- Shams University

Supervised by

Prof.Dr. Thanaa El-Sayed Ahmed Helal

Professor of Pathology
Faculty of Medicine- Ain Shams University

Prof.Dr. Ahmed Mohy El -din Zaki

Professor of Pathology
Faculty of Medicine- Ain Shams University

Prof.Dr. Ali Ahmed Ali Waheeb

Professor of Internal Medicine
Faculty of Medicine - Al-Azhar University

Prof.Dr. Naglaa Samier Ahmed

Professor of Pathology
Faculty of Medicine - Ain Shams University

Assist. Prof. Dr. Nehal Ahmed Radwan

Assistant Professor of Pathology
Faculty of Medicine - Ain Shams University

Faculty of Medicine
Ain Shams University
2019

بسم الله الرحمن الرحيم

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم الحكيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

First and foremost, I thank ALLAH for endowing me with health, patience, and knowledge to complete this work, as a part of generous help throughout my life.

Words stand short to express my deep respect and thanks to ***Prof.Dr. Thanaa El-Sayed Ahmed Helal,*** *Professor of Pathology, Faculty of Medicine- Ain Shams University, for her great assistance, valuable advices and her endless help to accomplish this work. I really have the honor to work under her supervision.*

I would like to extend my deepest thanks to ***Prof.Dr. Ahmed Mohy El -din Zaki,*** *Professor of Pathology, Faculty of Medicine- Ain Shams University, for his great support, fruitful advices and generous help throughout this work.*

I wish to introduce my great respect and thanks to ***Prof.Dr. Ali Waheeb****, Professor of Internal Medicine, Faculty of Medicine - Al-Azhar University, for the great help and suuport he has devoted to accomplish this work.*

I would like to express my great appreciation and respect to ***Prof.Dr. Naglaa Samier Ahmed,*** *Professor of Pathology, Faculty of Medicine - Ain Shams University, for her great outstanding support, unlimited help and valuable comments.*

I am deeply thankful to ***Assist Prof. Dr. Nehal Ahmed Radwan,*** *Assistant Professor of Pathology, Faculty of Medicine - Ain Shams University, for being there through all the work, for her sincere advices, unlimited help and endless encouragement.*

I am really greatful to my ***dear professors and colleagues*** *who have prayed for me, expressed concern and extended their hands.*

To ***my family, my beloved father, my dear husband, and my sweet doughters.*** *I am realy greatly indebted to you for providing me with love, encouragement and prayers throughout this work.*

Heba Ahmed Mahmoud Mohammed

List of Contents

Subject *Page No.*

List of Abbreviations ..... **i**
List of Tables ..... **vi**
List of Figures ..... **viii**
Introduction **1**
Aim of the Work **4**
Review of Literature
Epidemiology and prevalence of viral hepatitis C 5
Risk factors of infection and mode of transmission 9
Molecular Virology and pathogenetic mechanism of HCV 10
Immune responses and pathogenesis of hepatic injury in HCV infections 13
Clinical course and prognosis of HCV 23
Histopathology of Chronic Virus C Hepatitis 27
Pretratment requesits in interferone based therapy of chronic HCV 49
Treatment 60
Interferon based theraby 62
Predictors of interferon treatment response HCV 74
Hepatic progenitor/Stem cells 79
Cytokeratin 19 90
Neural cell adhesion molecule (CD56) 94
Materials and Methods **98**
Results ..... خطأ! الإشارة المرجعية غير معرّفة.
Discussion **147**
Summary **158**
Conclusion ..... خطأ! الإشارة المرجعية غير معرّفة.
Recommendations **163**
References **164**
Arbic Summary ..... **—**

List of Abbreviations

Abbr.	Full-term
A	: Activity grade based on the scoring system of METAVIR
AFP	: Alfa feto protein
Alb	: Albumin
ALT	: Alanine aminotransferase
BMI	: Body mass index
VBT	: Virological breakthrough
CAMs	: Cell adhesion molecules
CC	: Cholangiocarcinoma
CD	: Cluster of differentiation
CK19	: Cytokeratine 19
CTL	: Cytotoxic T-lymphocyte
DAB	: Di-AminoBenzidine
DR	: Ductular reaction
E	: Envelope
ECM	: Extracellular matrix
EDHS	: Egyptian Demographic Health Survey
EDTA	: Ethylene diamino tetraacetic acid
EFNA1	: A gene on chromosome 1q21-q22 that encodes ephrin-A1 protein
EGF	: Epithelial growth factor
EIAs	: Enzyme immunoassays

EpCAM : Epithelial cell adhesion molecule

ETR : End of treatment response

EVR : Early virological response

F : Fibrosis Stage based on the scoring system of METAVIR

FDA : Food and Drug Administration

FGF7 : Fibroblast growth factor 7

G0 : Mitotically quiescent state

G1-6 : Genotype 1-6

GGT : Gamma-Glutamyltransferase.

Hx&E : Hematoxylin and eosin

HA : Hepatocellular adenoma

HAI : Histologic activity index

HBV : Hepatitis B virus

HCC : Hepatocellular carcinoma

cHCC-CC : Combined hepatocellular-cholangiocarcinoma

HCV : Hepatitis C virus

HGF : Hepatic growth factor

HIV : Human immunodeficiency virus

HLA-C : Human leukocyte antigen C

HPCs : Hepatic stem/progenitor cells

HPF : High power field

IF : Intermediate filaments proteins

IFN : Interferon

IL-10R2 : Interleukin-10 receptor 2

IP-10 : IFN-γ-inducible protein

IPCs : Isolated progenitor cells

ISG : Interferon -stimulated genes

Jak-STAT : Janus kinase—signal transducers and activators of transcription

LCC : Large cell change

METAVIR : Meta-analysis of Histological Data in Viral Hepatitis

mRNA : Messenger Ribonucleic acid

NASH : Nonalcoholic steatohepatitis

NCAM : Neural cell adhesion molecule

NHANES : National Health and Nutrition Examination Surveys

NK : Natural killer

NS : Non-structural

NVR : No virological response

PAS : Periodic acid-Schiff (stain)

PAT : Parenteral antischistosomal therapy

PBMCs : Nuclear factor-κB (NF-κB) peripheral blood mononuclear cells

PBS : Phosphate Buffered Saline

P-C : Portacentral

PCR : Polymerase chain reaction

PDGF : Platlet drived growth factor

Peg-IFN : Pegylated interferon

P-P : Portal-portal

RBV : Ribavirin

RGT : Response-guided therapy

RNA : Ribonucleic acid

RVR : Rapid virological response

S : Steatosis degree according to Brunt's scale

SCC : Small cell change

SVR : Sustained virological response

TGF-β : Tissue growth factor-β

TH : T-helper lymphocyte

Thy-1 : Thymus cell antigen-1

TIMP : Tissue inhibitors of metalloproteinases

TLR : Toll-like receptor

TMA : Transcription-mediated amplification

TNF-α : Tumor necrosis factor-alpha

TWEAK : TNF-like weak inhibitor of apoptosis

USA : United States OF America

USP18 : Ubiquitin-specific peptidase 18

VBT : Virological breakthrough

VR : Virological relapse

WHO : World health Organiation

Wnt : The Name Wnt is a portmanteau of int and Wg and stands for "Wingless-related integration site"

List of Tables

Table No.	Title
Table (1):	Interpretation of HCV Assays 53
Table (2):	Algorithm for evaluation of the grades of activity according to the scoring system of METAVIR..... 44
Table (3):	American Association for the Study of Liver Diseases (AASLD) guide lines for Selection of Patients for Treatment..... 61
Table (4):	Summary of clinicopathological data of studied chronic HCV cases (no=120)..**خطأ! الإشارة المرجعية غير معرّفة.**
Table (5):	Relation between virological response and demographic, laboratory and histopathologic parameters..**خطأ! الإشارة المرجعية غير معرّفة**
Table (6):	Comparison between different HCV groups according to their response to treatment and their studied demographic, laboratory and histopathologic parameters..**شارة المرجعية غير معرّفة**
Table (7):	Median values of hepatic progenitor cells in the various groups of virological response.....**خطأ! الإشارة المرجعية غير معرّفة.**
Table (8):	Hepatic progenitor cells expression by CK19 and CD56 (NCAM) in demographic, laboratory and pathologic variables in all studied chronic HCV cases..**خطأ! الإشارة المرجعية غير معرّفة**

Table (9): Relationship between hepatic progenitor cells expression by CK19 and CD56 (NCAM)and other demographic, laboratory and pathologic variables in all studied chronic HCV cases..**خطأ! الإشارة المرجعية غير معرّفة.**

Table (10): Comparison between different grades of activity (A), different stages fibrosis (F) by METAVIR scoring and different degrees of steatosis (S) by Brunt's staging system system as regard the median of DR (CK19), the median of IPCs (CK19),the median of DR (CD56 (NCAM)) and the median of IPCs (CD56 (NCAM)) (Wilcoxan Rank Sum test)..**خطأ! الإشارة المرجعية غير معرّفة.**

List of Figures

Figure No.	Title
Figure (1):	Epidemic of hepatitis C virus (HCV) in the world 6
Figure (2):	HCV antibody prevalence (%) by major subdivision, EDHS 2008 8
Figure (3):	Genomic organization of hepatitis C polyprotein. 11
Figure (4):	Schematic representation of the life cycle of HCV 12
Figure (5):	Components of Antiviral Immune Response 14
Figure (6):	Interferon signal transduction 16
Figure (7):	NK cell function in chronic hepatitis C infection 22
Figure (8):	Schematic diagram showing the pathway of extracellular matrix (ECM) production and degradation. 58
Figure (9):	Schematic showing the four grades of portal-periportal activity (piecemeal necrosis) and confluent lobular necrosis according to Ishak's scoring system P-C, portal-central 42
Figure (10):	Schematic of the METAVIR algorithm..... 45
Figure (11):	Schematic showing METAVIR fibrosis stages F0, F1, F2, F3, and F4..... 46
Figure (12):	Structure of ribavirin..... 66

Figure (13): Effects of RBV on innate and adaptive immune responses 69

Figure (14): Graphic display of virological responses..... 73

Figure (15): Schematic overview of liver lobule 82

Figure (16): Liver stem cells in the canals of Hering, structures that connect bile ductules with parenchymal hepatocytes (bile duct and Hering canals are stained for cytokeratin 7) 84

Figure (17): Mechanisms of HPCs differentiation during adult regeneration 88

Figure (18): Pre-treatment HCV-RNA in the studied HCV cases (n=120)..**خطأ! الإشارة المرجعية غير معرّفة**

Figure (19): Groups of HCV cases according to their response to treatment..**خطأ! الإشارة المرجعية غير معرّفة**

Figure (20): Grade of activity by METAVIR scoring system in the studied HCV cases (n=120)..**خطأ! الإشارة المرجعية غير معرّفة**

Figure (21): Stage of fibrosis by METAVIR scoring systemin the studied HCV cases (n=120).....**خطأ! الإشارة المرجعية غير معرّفة.**

Figure (22): Degree of steatosisin the studied HCV cases (n=120). .....**خطأ! الإشارة المرجعية غير معرّفة.**

Figure (23): Median ductular reaction (DR) expression by CK19 in the various groups of virological response..**خطأ! الإشارة المرجعية غير معرّفة**

Figure (24): Comparison between responders and nonresponders regardingthe median ductular reaction (DR) expression by CK19 *(Wilcoxn Rank Sum test)*..**خطأ! الإشارة المرجعية غير معرّفة**

Figure (25): Median isolated progenitor cells (IPCs) expression by CK19 in the various groups of virological response..**خطأ! الإشارة المرجعية غير معرّفة.**

Figure (26): Comparison between responders and nonresponders regardingthe median isolated progenitor cells (IPCs) expression by CK19 *(Wilcoxn Rank Sum test)*..**خطأ! الإشارة المرجعية غير معرّفة.**

Figure (27): Median ductular reaction (DR) expression by CD56 (NCAM) in the various groups of virological response..**لإشارة المرجعية غير معرّفة.**

Figure (28): Comparison between responders and nonresponders regardingthe median ductular reaction (DR) expression by CD56 (NCAM) *(Wilcoxn Rank Sum test)*..**شارة المرجعية غير معرّفة.**

Figure (29): Median isolated progenitor cells (IPCs) expression by CD56 (NCAM) in the various groups of virological response..**لإشارة المرجعية غير معرّفة.**

Figure (30): Comparison between responders and nonresponders regardingthe median isolated progenitor cells (IPCs) expression by CD56 (NCAM)*(Wilcoxn Rank Sum test).* .....**خطأ! الإشارة المرجعية غير معرّفة.**

Figure (31): Comparison between different grades of activity by METAVIR scoring system (A) as regard the median of DR (CK19) (I), the median of IPCs (CK19) (II), the median of DR (CD56 (NCAM)) (III) and the median of IPCs (CD56 (NCAM)) (IV). Capital letters represent the significance between groups **(Wilcoxan Rank Sum test)**...**خطأ! الإشارة المرجعية غير معرّفة.**